Sponsored Events (Non-Accredited)
These company-based informational sessions provide delegates with non-accredited educational opportunities to learn the latest in therapeutics.
2026 Corporate Therapeutic Symposia Schedule
Non-Accredited
Lunch will be served during all Corporate Therapeutic Symposia; No other lunches are available at the International Congress.
Sunday, October 4, 12:15 – 13:15
AbbVie
Navigating The Parkinson’s Journey: Changing Needs & Timely Interventions
This symposium will explore the evolving management of Parkinson’s disease across stages, with a focus on recognizing and treating the complex phase. Through expert presentations and a structured debate, the session will examine care gaps, the burden of complex phase disease, and the role of device-aided therapies in supporting timely, individualized treatment decisions
Speakers: Alfonso Fasano, Canada; Florin Gandor, Australia; Shivam Om Mittal, UAE; Marina Picillo, Italy
Monday, October 5, 12:30 – 13:30
BlueRock Therapeutics (Bayer)
Replacing What Was Lost: The Potential of Cell Therapy in Parkinson’s Disease
Examining the potential of cell therapy to restore lost dopaminergic neurons in Parkinson's disease.
Speakers: Claire Henchcliffe, MD,DPhil, FAAN, FANA; Robert Hauser, MD, MBA; Stuart Isaacson, MD
H. Lundbeck A/S
Decoding MSA: from prodromal signs to clinical progression and integrative biomarkers
This session on multiple system atrophy will discuss the importance of prodromal MSA detection, variability in clinical progression, and emerging biomarker strategies.
Speakers: Prof Horacio Kaufmann (US; Chair), Prof Wassilios Meissner (France), Prof Hirohisa Watanabe (Japan)
Supernus Pharmaceuticals
A Different Path to More GOOD ON Time in Parkinson’s
Join Daniel Kremens, MD, JD, and Rajesh Pahwa, MD, as they discuss a different path to more GOOD ON time in Parkinson’s.
Speaker: Daniel Kremens, MD, JD and Rajesh Pahwa, MD
Tuesday, October 6, 12:45 – 13:45
AskBio (Bayer)
Exploring the Potential of Regenerative Research: Gene Therapy in Parkinson’s Disease
Together, these experts will offer highly complementary perspectives on emerging gene therapies and other disease-modifying approaches in Parkinson’s disease. Their collective expertise will provide attendees with a comprehensive view of the scientific advances, clinical challenges, and future directions shaping the field of regenerative medicine and potentially transforming the landscape of Parkinson’s disease research.
Speakers: Claire Henchcliffe, MD, DPhil; Alessandra Fanciulli, MD, PhD; Andres Deik, MD, MSEd
Praxis Precision Medicines
A Breakthrough in Essential Tremor: Phase 3 Evidence for Ulixacaltamide as the First Targeted Therapy
Description TBA.
2026 Innovation Showcase Schedule
Non-Accredited
Monday, October 5, 09:45 - 10:15
Amneal Pharmaceuticals
ELEVATE-PD: Advancing Parkinson's Disease Management Through Optimized Levodopa Delivery
IPX203 (CREXONT®) is a novel extended-release carbidopa-levodopa formulation with a unique mucoadhesive polymer technology, designed to optimize levodopa absorption, prolong plasma levodopa exposure, and extend the duration of clinical benefit. ELEVATE-PD is a real-world study evaluating the safety, efficacy, and treatment outcomes associated with transitioning patients with Parkinson's disease from other levodopa-based therapies to IPX203 under real-world conditions. This Innovation Showcase will present emerging real-world evidence on the impact of IPX203 on both motor and non-motor symptoms. The session will explore how optimized levodopa delivery may address unmet needs in Parkinson's disease management and provide insights into the clinical benefits observed following conversion from existing levodopa regimens.
Speakers: Dr. Stuart Isaacson, MD, MBA, Dr. Robert Hauser, MD, FAAN, MBA
Monday, October 5, 15:30 - 16:00
Medtronic
Title to be announced
Tuesday, October 6, 09:45 - 10:15
Boston Scientific
Title to be announced